Atogepant Cuts Migraine Days in Patients With Prior Treatment Failure

Atogepant led to a reduction in mean monthly migraine days in patients with episodic migraine who previously failed 2 to 4 treatments.

Related Keywords

United States ,American ,Atogepant Qulipta ,Drug Administration ,American Academy Of Neurology Annual Meeting ,Neurology Annual ,